Observational studyScientific reports2026
Evaluation of the diagnostic value of three YiDiXie tests in prostate cancer: an observational prospective single-center study.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-Specific Antigen (PSA) and Magnetic Resonance Imaging (MRI) are widely used in the diagnosis of prostate cancer (PCa), but relatively inaccurate results may affect diagnosis and treatment. There is an urgent need to find convenient, economical and non-invasive diagnostic methods to reduce the false positive and false negative rates of PSA or MRI. The purpose of this study was to evaluate the diagnostic value of YiDiXie-30, YiDiXie-32, and YiDiXie-48 in prostate cancer. This study ultimately included 562 participants (malignant group, n = 357; benign group, n = 205). Residual serum samples from the participants were collected and tested using the YiDiXie all-cancer detection kit to assess the sensitivity, specificity, positive likelihood ratio(PLR) and negative likelihood ratio(NLR) of YiDiXie-30, YiDiXie-32 and YiDiXie-48, respectively. Receiver-operating characteristic (ROC) curves’ analyses were included in this study. The sensitivity of YiDiXie-30 was 81.2%, with a specificity of 93.2%, positive likelihood ratio (PLR) of 11.9, and negative likelihood ratio (NLR) of 0.20. Corresponding values for YiDiXie-32 were 93.6%, 85.4%, 6.4, and 0.08, while those for YiDiXie-48 were 99.4%, 61.5%, 2.6, and 0.01, respectively. Further studies found that YiDiXie-30, YiDiXie-32, and YiDiXie-48 yielded similar results in patients with positive or negative PSA or MRI. The results of the single-center study showed that the YiDiXie tests were highly effective in diagnosing prostate cancer, with clearly different levels of sensitivity and specificity. The YiDiXie tests show strong diagnostic utility for prostate cancer within the particular clinical and population context of this study cohort, especially the YiDiXie-30 (extremely high PLR) and YiDiXie-48 ((extremely low NLR). This method has the potential to significantly reduce needless biopsies brought on by false-positive PSA or MRI results. The two main issues of “excessively high false-positive rates” and “excessively high false-negative rates” in PSA or MRI are anticipated to be addressed.Clinical Research Registry Number: ChiCTR2200066840.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.